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that age, disease duration, and severity of levodopa-related mo-
tor complications were not predictive, but the decisions to per-
form surgery on the oldest patients and/or patients with gait and 
postural disorders who are poorly responsive to levodopa should 
be weighed carefully. We analyzed the factors related to long-
term outcome from our data and discussed these in this paper. 
In addition, we reviewed the patients who improved dyskinesia 
without sufficient decrease of levodopa equivalent dose (LED) 
and discussed such paradoxical improvement.
MATERIALS AND METHODS
We performed STN DBS for total 139 PD between February 
2000 and October 2006 in our institute. We reviewed 75 pa-
INTRODUCTION
The results of subthalamic nucleus (STN) deep brain stimula-
tion (DBS) in Parkinson’s disease (PD) are well-studied2,3,7-9,11,16-18, 
23,25,27,28,34,36,37). The benefits of STN DBS are not in doubt, and are 
supported even by long-term follow-up data.
Factors related to surgical outcomes are major concerns in 
STN DBS. Guehl et al.12) reported that age, intensity of axial 
symptoms and Unified Parkinson’s Disease Rating Scale (UP-
DRS) II off-medication score before surgery predict dysarthria/
hypophonia and postural instability after surgery. Tsai et al.32) 
reported that older age and non-dopaminergic-responsive axial 
disability were poor prognostic factors. Welter et al.35) also dis-
cussed the clinical predictive factors of STN DBS and insisted 
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in UPDRS part III. For all analyses, a p<0.05 threshold for sig-
nificance was chosen.
RESULTS
Demography of the patients
The mean age of the patients at surgery was 57.60±10.58 (range 
36-77) years, and the sex ratio (male : female) was 26 : 26. Mean 
symptom duration was 10.25±4.84 (range 5-22) years, and me-
dian follow-up duration was 57.48 (range 37-110) months as 
shown in Table 1. Preoperative ADL, BDI, MMSE, CDR, daily 
LED and levodopa response (in UPDRS part III) are shown in 
Table 2.
Preoperative state versus final follow-up state
There was remarkable improvement between the preopera-
tive state and final follow-up state. The clinical courses over 3 
years were shown in Fig. 1. The improvement after surgery 
maintained through whole follow-up period. Preoperative UP-
DRS part III without medication was 43.19±15.31 and improved 
to 29.65± 12.44 (p<0.001) finally. LED decreased from 957.16± 
487.10 to 603.41±359.03 (p<0.001). UPDRS part II with/with-
out medication, UPDRS part IV, H&Y, and ADL scores showed 
statistically significant improvement (Table 2). UPDRS part I, 
MMSE and BDI did not show any changes throughout the en-
tire follow-up duration. Only CDR score showed a statistically 
significant increase in long-term follow-up (p<0.001) (Table 2).
tients with fully available medical record for analysis. Finally, we 
enrolled 52 patients follow-up for at least 3 years. All the patients 
were diagnosed with idiopathic PD by an expert movement dis-
order neurologist and a neurosurgeon. Preoperatively, the UP-
DRS, Modified Hoehn and Yahr staging (H&Y), Schwab and 
England Activity of Daily Living (ADL) scale, Beck Depression 
Inventory (BDI), Mini-Mental Status Examination (MMSE), 
Clinical Dementia Rating (CDR), and basic neuropsychological 
tests were assessed. UPDRS part II and III were evaluated with 
and without medication respectively. Levodopa challenge tests 
were performed to determine whether patients were suitable 
for the surgery. That is, UPDRS part III was evaluated by expert 
movement disorder neurologist after being “off ” levodopa 
medication for a minimum of 12 hours. Then, UPDRS part III 
evaluation was performed again by same neurologist after le-
vodopa administration (usually 1.5 times the dose). We per-
formed the surgery if the patient showed greater than 33% im-
provement of UPDRS part III in levodopa challenge test. We 
excluded the patients with Parkinsonism and any cognitive and 
psychiatric problems. Surgery was performed in a single day, 
from bilateral leads implantation to implantable pulse genera-
tors insertion. After surgery, the items that had preoperatively 
evaluated assessed during follow-up.
Statistical analysis
The statistical analysis was performed using SPSS 13.0 (SPSS 
Inc., Chicago, IL, USA). We first compared the data between 
the preoperative state and the follow-up state. To compare these 
differences, the paired t-test was used or parametric variables 
such as LED and the nonparametric Wilcoxon signed-ranked 
test was used for nonparametric variables such as UPDRS 
scores. Second, factors such as age, sex, symptom duration, pre-
operative ADL, BDI, CDR, MMSE, H&Y, LED and levodopa 
responsiveness were analyzed by linear regression to determine 
if they predicted the results of STN DBS. 
We divided the sample according to sex, 
age (≤65 years, >65), symptom dura-
tion (≤10 years, >10), H&Y (≤3, >3) 
and average levodopa responsiveness 
(≤50.02%, >50.02%), ADL (≤60, >70), 
preoperative LED (≤900 mg/day, >900) 
and compared the long-term follow-up 
data of each group. In order to determine 
the differences between the groups, t-
tests and Wilcoxon signed-ranked tests 
were performed. Test variables were 
differences in respective scores between 
preoperative state and final follow-up 
state in H&Y, ADL, UPDRS score, DBI, 
MMSE, CDR, and LED. Finally, we 
compared the previous profiles in the 
patients that showed an increase in LED 
and the patients with aggravated results 
Table 1. Patient demographic and preoperative clinical data
Characteristic Value (range)
Mean age at surgery (years old)     57.60±10.58 (36-77)
Male : Female 26 : 26
Mean symptom duration (years) 10.25±4.84 (5-22)
Median follow-up duration (months) 57.48 (37-110)
Table 2. Comparison between preoperative state and final follow-up state in long-term follow-up
Preoperative (n=52) Follow-up (n=52) p value
UPDRS I   3.60±2.38   3.54±2.38    0.718
UPDRS II (on) 14.63±6.40 10.85±5.36 <0.001
UPDRS II (off) 21.33±7.27 19.54±6.74    0.017
UPDRS III (on)   21.62±10.70 18.79±9.11 <0.001
UPDRS III (off)   43.19±15.31   29.65±12.44 <0.001
UPDRS IV   7.63±4.90   4.85±3.74 <0.001
H&Y   3.07±0.76   2.07±0.72   0.001
ADL   60.58±17.08   76.92±14.22 <0.001
CDR   0.13±0.70   0.41±0.79 <0.001
BDI 20.25±7.54   21.65±10.22   0.157
MMSE 27.65±2.76 27.44±1.82   0.059
LED (mg/day)   957.16±487.10   603.41±359.03 <0.001
UPDRS : Unified Parkinson Disease Rating Scale, H&Y : Modified Hoehn and Yahr stage, ADL : Schwab and Eng-
land Activities of Daily Living Scale, CDR : Clinical Dementia Rating, BDI : Beck Depression Inventory, MMSE : Mini-
Mental Status Examination, LED : Levodopa Equivalent Dose per day, on : with medication, off : without medica-
tion, Preoperative : preoperative state, Follow-up : final follow-up state
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ceeded in multivariate analysis. Preoperative ADL (p<0.001) 
and LED (p=0.013) were related to the improvement in UPDRS 
part II with medication (R2=0.464). In addition, the magnitude 
of preoperative levodopa responsiveness (p=0.006) was related 
to the improvement in UPDRS part II without medication (R2= 
0.355). The magnitude of preoperative levodopa responsiveness 
(p=0.036) was related to the improvement in UPDRS part III 
with medication (R2=0.332).
In order to determine whether factors such as gender, age, 
H&Y stage, symptom duration and the intensity of preopera-
tive levodopa response influence the results of STN DBS, we 
divided the study sample into groups and compared them. In 
the groups divided by sex, male patients showed a greater de-
crease in UPDRS part II score (only without medication, 
p=0.039) and part III score (only without medication, p= 
0.033) than females. In the groups divided by age, young pa-
tients showed greater improvement in H&Y stage (p=0.006). 
In H&Y groups, H&Y 1-3 groups showed greater improve-
ment in UPDRS IV than did the H&Y 4-5 groups (p=0.025). 
In levodopa responsiveness groups, more improvement in UP-
DRS part III score (only without medication, p=0.034) was 
shown as stronger response to levodopa preoperatively (Fig. 
2). There were no significant differences in the groups divided 
by other variances.
Thirteen patients whose LED increased after long-term 
follow-up
LED decreased from 957.16±487.10 to 603.41±359.03 
(p<0.001) (Table 2). However, there were 13 patients whose LED 
increased at the final follow-up rather than preoperatively. The 
sex ratio of theses patient was 5 : 8 (male : female), and their 
Factors related to long-term results
Several factors were analyzed to determine if they predicted 
improvement in UPDRS parts II and III with or without medica-
tion, respectively (Table 3). In the univariate analysis, preopera-
tive ADL (p=0.015, R2=0.112) and the magnitude of preoperative 
levodopa response (p=0.007, R2=0.136) were shown to predict 
the improvement in UPDRS part II without medication, and pre-
operative ADL (p=0.003, R2=0.160) and LED (p=0.023, 
R2=0.099) were positively correlated with the improvement in 
UPDRS part II with medication. Proper understanding of the 
magnitude of preoperative levodopa response (p=0.004, R2= 
0.156) could lead to consistent improvement in UPDRS part III 
with medication.
The factors which were significant in univariate analysis pro-
Fig. 1. The clinical outcomes after bilateral subthalamic nucleus stimulation. *All 52 patients were evaluated.
Fig. 2. More improvement in Unified Parkinson’s Disease Rating Scale 
part III score (only without medication) is shown as stronger response to 
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thought to be due to the natural course of PD. Other basic neuro-
psychological profiles such as UPDRS part I, MMSE and BDI did 
not show any changes in long-term follow-up. In the literature, it 
was reported that STN DBS cannot stop the natural progression 
of PD11,36). Kaiser et al.15) reviewed 38 PD patients who under-
went STN DBS and mentioned that their psychosocial profiles 
transiently improved at 12 months after surgery but returned to 
baseline at 36 months. Tsai et al.33) reported that neuropsycho-
logical effects after STN DBS were closely related to anterior lo-
mean age was 59.85± 9.26 years (range, 
40-76). UPDRS part II off-medication, 
III off-medication, H&Y, and ADL in 
the final follow-up state showed statisti-
cally significant improvement com-
pared with preoperative state (Table 4). 
UPDRS part IV decreased slightly de-
spite the increased medication dosage, 
although the change was not statistically 
significant.
Nine patients whose UPDRS III 
score deteriorated after long-term 
follow-up
Overall, the patients showed improve-
ment after STN DBS; however, 9 pa-
tients experienced aggravation in UP-
DRS part III (with/without medication) 
after long-term follow-up (Table 5). The 
sex ratio of these patients was 3 : 6 (male : 
female), and their mean age was 58.44± 
12.32 years (range, 37-77). No other 
scores showed statistically significant ag-
gravation, and ADL showed improve-
ment (p=0.008). Among these 9 pa-
tients, LED and UPDRS part I score 
decreased in all except two patients, and 
UPDRS part IV score decreased in all 
except three.
Complications
There was no mortality in our series. 
Complications related to the surgical 
procedures were hemorrhage and infec-
tion. Three patients showed infection, 
and the leads at the infected sites were 
removed. Disconnection of leads oc-
curred in one patient, in whom the lead 
was exchanged. Intracranial hemorrhage 
occurred in one patient who recovered 
with some disabilities. The adverse ef-
fects related to chronic stimulation were 
mostly tolerable with parameters con-
trolled in the outpatient department.
DISCUSSION
Long-term follow-up of STN DBS
In general, STN DBS results in improvement in the motor 
symptoms of PD2,11,36). In our study, UPDRS part II with medica-
tion, UPDRS part III with/without medication, UPDRS part IV, 
LED, H&Y, and ADL showed improvement after long-term fol-
low-up. However, CDR increased in long-term follow-up and is 
Table 3. Factors related to long-term results of STN DBS 
Univariate (p value) Multivariate (p value)
II on II off III on III off II on II off III on III off
Age 0.592 0.244 0.890 0.246 0.140 0.515 0.280 0.748
Sex 0.734 0.959 0.071 0.127 0.667 0.486 0.036 0.076
Sx duration 0.846 0.625 0.933 0.562 0.327 0.531 0.432 0.920
Follow-up 0.580 0.246 0.742 0.147 0.131 0.491 0.662 0.130
ADL 0.003 0.015 0.358 0.706 0.003 0.110 0.207 0.794
BDI 0.568 0.641 0.310 0.111 0.576 0.647 0.086 0.053
CDR 0.342 0.627 0.733 0.824 0.268 0.588 0.693 0.574
MMSE 0.264 0.222 0.508 0.824 0.261 0.715 0.747 0.319
H&Y 0.923 0.118 0.932 0.488 0.024 0.897 0.167 0.498
Dopa response 0.127 0.007 0.004 0.050 0.103 0.006 0.036 0.145
LED 0.023 0.155 0.055 0.654 0.013 0.031 0.085 0.807
p-value <0.05. II : Unified Parkinson Disease Rating Scale part II, III : Unified Parkinson Disease Rating Scale 
part III, on : with medication, off : without medication, Sx : symptom, ADL : Schwab and England Activities of 
Daily Living Scale, BDI : Beck Depression Inventory, CDR : Clinical Dementia Rating, MMSE : Mini-Mental Status 
Examination, H&Y : Modified Hoehn and Yahr stage, LED : Levodopa Equivalent dose per day, STN : subthalamic 
nucleus, DBS : deep brain stimulation
Table 4. Summary of 13 patients whose LED increased at final follow-up
Preop Follow-up p value
Male : Female 5 : 8
Mean age at surgery (years old) 59.85±9.26 (range, 40-76)
Median follow-up duration 
  (months)
            57.62 (range, 42-100)
Sx duration (years)           9.00 (range, 5-16)
UPDRS I   2.85±1.77   2.08±1.50 0.227
UPDRS II (on) 13.62±6.42 12.23±4.69 0.205
UPDRS II (off) 22.23±9.47 17.31±5.19 0.013
UPDRS III (on)   19.46±11.90 18.69±9.43 0.649
UPDRS III (off)   40.46±16.95   28.54±14.97 0.003
UPDRS IV   6.77±4.83   5.31±3.71 0.653
H&Y   3.27±0.97   2.69±0.80 0.016
ADL   60.77±17.06   74.62±17.13 0.011
CDR   0.12±0.22   0.35±0.55 0.102
BDI 17.23±6.88 17.69±9.10 0.646
MMSE 27.38±3.40 27.77±1.79 0.523
LED (mg/day)   592.31±299.01   898.27±314.91 0.001
Preop : preoperative state, Final follow-up : final follow-up state, Sx : symptom, H&Y 1-3 : the number of 
patients whose Hoehn and Yahr stage was 1-3, LED : levodopa equivalent dose per day, ADL : Schwab and 
England Activities of Daily Living Scale, UPDRS : Unified Parkinson’s Disease Rating Scale, CDR : Clinical De-
mentia Rating, BDI : Beck Depression Inventory, MMSE : Mini-Mental Status, on : with medication, off : without 
medication
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medication was significantly greater in 
men than in women. Romito et al.24) 
mentioned poorer transient outcomes 
in women patients, similar to our re-
sults. Marceglia et al.19) reported differ-
ences in local field potential of STN be-
tween male PD patients and female PD 
patients, which may be important for 
understanding gender-specific features 
of neurodegenerative disorders. Con-
versely to our results, Hariz et al.13) con-
cluded that stereotactic surgery for PD 
patients should be offered more often 
and earlier in women since female pa-
tients had longer duration of disease 
and higher H&Y scale but experienced 
greater benefit than male patients in 
ADL, emotions, and social life. Accollar 
et al.1) reported that women had greater 
improvement in ADL. These gender-
related differences might be related to 
sex hormones, hormonal modulation 
on dopaminergic receptors and gene 
expression or anatomical and chemical 
differences, while the subjective an-
swers about ADL might be influenced 
by social and cultural differences.
Effect of age on STN DBS
It is uncertain whether the results of STN DBS are affected by 
age. H&Y stage improvement was greater in the young age group 
than in the elderly group in our study. We did not exclude el-
derly patients, and elderly patients in our series accounted for 
28.8% (15/52) of the total patients. Previous reports have shown 
that the results of STN DBS are related to age. Tagliati et al.31) 
and Simuni et al.30) reported that age was not a predictor of STN 
DBS outcome. Ory-Magne et al.20) reported their results accord-
ing to patient age and insisted that UPDRS parts II, III, cognitive 
impairment, and quality of life had no correlation with age, al-
though there was a significant increase in symptomatic cerebral 
hemorrhage in the elderly group. Derost et al.6) reported that 
postoperative quality of life improved up to 2 years only in young 
PD patients. In our series, only H&Y stage improvement was 
affected by age, and other clinical data were not different be-
tween young and elderly patients. We believe that age alone 
does not determine long-term surgical outcome nor should it 
be an exclusion criterion of surgical indication.
LED increase after long-term follow-up
STN DBS can decrease LED and levodopa-induced motor 
complications. Interestingly, the ADL of PD patients showed im-
provement after surgery even though the LED of those patients 
increased in our series. H&Y, UPDRS parts II and III (without 
cation of the active electrode contact within the ventral STN. 
Weaver et al.34) reported the effectiveness of DBS compared with 
best medication treatment in randomized controlled trial. Ger-
vais-Bernard et al.11) reported on 42 prospective PD patients 
treated with STN DBS and showed that DBS resulted in long-
term benefits but did not prevent disease progression. Krack et 
al.18) reported 5 years of prospective follow-up data in 49 PD pa-
tients and concluded that there was marked improvement in 
motor function without medication and dyskinesia with medi-
cation, but worsening of akinesia, speech, postural stability, 
freezing of gait, and cognitive function that was consistent with 
the natural history of PD. Wider et al.36) also reported that STN 
DBS is an effective treatment, but that disease progression oc-
curs in long-term follow-up. Erola et al.9) reported that bilateral 
STN DBS improved health-related quality of life in 27 PD pa-
tients during 12 months. Improvement in motor function and 
medication-related motor complications must be definitely es-
tablished, although worsening of some components such as 
speech, axial symptom, and cognition due to natural course of 
PD seems to be inevitable.
Effect of gender on STN DBS
The hypothesis that gender could affect the results of STN 
DBS is mentioned by a few lieteratures1,24). In our series, the 
magnitude of improvement in UPDRS parts II and III without 
Table 5. Summary of 9 patients whose UPDRS part III off score was aggravated in the final follow-
up state
Preop Follow-up p value
Male : Female 3 : 6
Mean age at surgery (years old) 58.44±12.32 (range, 37-77)
Median follow-up duration 
  (months)
            54.47 (range, 43-72)
Levodopa response 
  (%, in UPDRS III)
59.90±12.07
Sx duration (years)           10.40 (range, 6-20)
UPDRS I   3.56±3.84   1.78±1.79 0.688
UPDRS II (on)   6.33±2.50 12.00±7.63 0.289
UPDRS II (off) 15.67±4.00 17.33±6.65 0.766
UPDRS III (on)   9.67±5.27 18.00±7.81 0.039
UPDRS III (off)   31.67±12.36   35.00±11.42 0.031
UPDRS IV   7.11±5.28   5.44±4.10 0.727
H&Y   2.72±0.62   2.33±0.43 0.125
ADL   68.89±13.64   83.33±14.14 0.008
CDR   0.06±0.17   0.22±0.26 0.250
BDI 15.33±4.09 19.89±9.35 0.180
MMSE 26.67±2.45 26.67±1.50 0.453
LED (mg/day) 1112.78±651.05   720.56±336.62 0.180
Preop : preoperative state, Final follow-up : Last follow up state, Sx : symptom, H&Y 1-3 : the number of 
patients whose Hoehn and Yahr stage was 1-3, LED : levodopa equivalent dose per day, ADL : Schwab and 
England Activities of Daily Living Scale, UPDRS : Unified Parkinson’s Disease Rating Scale, CDR : Clinical De-
mentia Rating, BDI : Beck Depression Inventory, MMSE : Mini-Mental Status, on : with medication, off : without 
medication
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not included in this study, it would be a very important factor 
for outcomes after STN DBS. The authors performed surgery 
under the local anesthesia. Microelectrode recording and intra-
operative stimulation test were performed in all cases. Also, we 
confirmed the position of intracranial electrode in postopera-
tive MRI. The accuracy of electrode position and clinical out-
comes were already reported by the authors5). However, a few 
studies on the electrode position and clinical outcomes were re-
ported. Peak et al.21,22) reported that more accurate electrode 
positioning in the STN is very important factor for better out-
comes after STN DBS.
CONCLUSION
STN DBS showed definite and marked improvement in ad-
vanced idiopathic PD. The intensity of preoperative levodopa re-
sponse was strongly related to motor improvement and ADL, 
while preoperative ADL and LED were strongly related to ADL 
improvement after STN DBS. In addition, STN DBS can improve 
the levodopa-induced motor complications even without reduc-
tion of LED. The reduction of levodopa-induced motor compli-
cations in advanced disease can improve ADL of PD patients af-
ter STN DBS. We do not know exactly how levodopa-induced 
motor complications are ameliorated after STN DBS, but the 
mechanism is probably more than secondary LED reduction 
from improved parkinsonian symptoms and likely to stabilize the 
motor circuits or to modulate the dopamine synaptic system.
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and striatal synaptic changes.
The mechanism of levodopa-induced motor complication is 
still under investigation at the interface between clinical and ba-
sic neuroscience4,26,29). The risk factors for motor complications 
are known as young onset age, severe disease, longer duration 
of levodopa therapy, high dose of levodopa and genetic predis-
position14,29). Recently, the understanding of the mechanism was 
expanded to include pre-synaptic abnormalities in dopamine 
release and clearance, molecular and synaptic adaptations in 
the striatum, and microvascular changes induced by levodopa4). 
As our cases showed postoperative clinical improvement al-
though LED increased, the mechanism of STN DBS can affect 
motor circuits and improve levodopa-induced motor complica-
tions is still obscure but is not simply due to reduction of LED.
Deterioration in UPDRS III score after long-term follow-up
The patients who deteriorated in motor function (UPDRS part 
III) in long-term follow-up did not experience aggravated ADL 
but rather improvement (p=0.008). These patients showed good 
preoperative response to levodopa, 59.90%, which was greater 
than that of the overall population in our series. The cause of 
deterioration in UPDRS part III was unclear in our study but 
was assumed to involve the aging process and disease progres-
sion. On the other hand, ADL improved in these patients and is 
closely related to motor fluctuation and drug-induced dyskine-
sia in advanced PD patients26). STN DBS can effectively reduce 
the motor complications closely related to ADL. Considering 
the small number of cases included in this study, the results that 
7 of 9 patients improved in LED and 6 of 9 patients improved in 
UPDRS IV should be carefully considered. These factors such 
as LED reduction and levodopa-induced complication relief are 
thought to affect ADL improvement in these patients.
Intracranial electrode position and clinical outcomes 
after STN DBS
Even though the factor of intracranial electrode position was 
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